Should I buy or sell Genelux stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GNLX shares. View GNLX analyst ratings or view top-rated stocks .

What is Genelux's stock price target for 2024?

4 Wall Street research analysts have issued twelve-month price targets for Genelux's stock. Their GNLX share price targets range from $30.00 to $40.00. On average, they expect the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 234.6% from the stock's current price. View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts .

How have GNLX shares performed in 2023?

Genelux's stock was trading at $6.01 at the beginning of 2023. Since then, GNLX stock has increased by 74.0% and is now trading at $10.46. View the best growth stocks for 2023 here .

Are investors shorting Genelux?

Genelux saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 789,200 shares, a decrease of 8.8% from the October 31st total of 865,800 shares. Based on an average daily volume of 228,700 shares, the days-to-cover ratio is presently 3.5 days. Currently, 4.1% of the company's shares are short sold. View Genelux's Short Interest .

When is Genelux's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our GNLX earnings forecast .

When did Genelux IPO?

(GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

Who are Genelux's major shareholders?

Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Provident Wealth Management LLC (1.36%), AE Wealth Management LLC (0.79%), Northern Trust Corp (0.61%), Charles Schwab Investment Management Inc. (0.56%), Bank of New York Mellon Corp (0.22%) and AMG National Trust Bank (0.19%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu. View institutional ownership trends .

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Genelux Stock Price, News & Analysis (NASDAQ:GNLX)

$10.46

-0.41 (-3.77%)

(As of 11/28/2023 ET)

Compare

Today's Range: $10.28
▼
$11.16
50-Day Range: $10.38
▼
$28.77
52-Week Range: $5.35
▼
$40.98

Volume: 115,415 shs
Average Volume: 127,583 shs
Market Capitalization: $279.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.00

Genelux MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 234.6% Upside
$35.00 Price Target
Short Interest: Healthy
4.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.16
Based on 12 Articles This Week
Insider Trading: Selling Shares
$8.74 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.03) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

350th out of 949 stocks

Biotechnology Industry

4th out of 19 stocks

3.5

Analyst's Opinion

Consensus Rating
Genelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.00, Genelux has a forecasted upside of 234.6% from its current price of $10.46.
Amount of Analyst Coverage
Genelux has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
4.07% of the float of Genelux has been sold short.
Short Interest Ratio / Days to Cover
Genelux has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Genelux has recently decreased by 8.85%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Genelux does not currently pay a dividend.
Dividend Growth
Genelux does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GNLX.

1.8

News and Social Media Coverage

News Sentiment
Genelux has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Genelux this week, compared to 1 article on an average week.
MarketBeat Follows
Only 3 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,735,376.00 in company stock.
Percentage Held by Insiders
11.70% of the stock of Genelux is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.77% of the stock of Genelux is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Genelux are expected to grow in the coming year, from ($1.03) to ($0.60) per share.

See Top Rated MarketRank™ Stocks Here

About Genelux Stock (NASDAQ:GNLX)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNLX Stock News Headlines

November 28, 2023 | americanbankingnews.com

Genelux (NASDAQ:GNLX) Coverage Initiated by Analysts at HC Wainwright

November 27, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Genelux (GNLX) with Buy Recommendation

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 27, 2023 | msn.com

Genelux gets fast track status for Olvi-Vec in ovarian cancer

November 27, 2023 | msn.com

HC Wainwright starts Genelux at buy, cites Olvi-Vec potential

November 27, 2023 | markets.businessinsider.com

Genelux Says FDA Grants Fast Track Designation For Olvi-Vec To Treat Ovarian Cancer

November 27, 2023 | finance.yahoo.com

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

November 25, 2023 | americanbankingnews.com

Genelux (NASDAQ:GNLX) PT Lowered to $30.00

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 23, 2023 | benzinga.com

Genelux VP Sold $191K In Company Stock

November 18, 2023 | americanbankingnews.com

Brookline Capital Management Equities Analysts Cut Earnings Estimates for Genelux Co. (NASDAQ:GNLX)

November 17, 2023 | finance.yahoo.com

Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%

November 15, 2023 | msn.com

Genelux GAAP EPS of -$0.20 misses by $0.02

November 14, 2023 | finance.yahoo.com

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

October 31, 2023 | morningstar.com

Genelux Corp GNLX

October 27, 2023 | msn.com

Genelux 10% owner Aladar Szalay discloses sale of 5,704 shares

October 27, 2023 | benzinga.com

10% Owner of Genelux Makes $110K Sale

October 26, 2023 | msn.com

Genelux Corporation 10% owner discloses sale of 49,987 shares

October 26, 2023 | benzinga.com

Genelux Insider Trades Send a Signal

October 26, 2023 | benzinga.com

VP at Genelux Exercises Options Worth $97K

October 11, 2023 | benzinga.com

Genelux 10% Owner Trades Company's Stock

October 6, 2023 | msn.com

Genelux (GNLX) Price Target Increased by 8.99% to 35.02

October 5, 2023 | benzinga.com

Genelux Recent Insider Activity

September 28, 2023 | benzinga.com

Genelux VP Acquires 5,200 Shares After Exercising Company Stock Options

September 28, 2023 | benzinga.com

Genelux 10% Owner Sold $1.03M In Company Stock

September 26, 2023 | benzinga.com

10% Owner At This Health Care Company Sells $462K of Stock

September 21, 2023 | benzinga.com

10% Owner At This Health Care Company Sells $1.56M of Stock

See More Headlines

Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GNLX
CUSIP: N/A
CIK: 1231457
Web: www.genelux.com
Phone: 805-267-9889
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.00
High Stock Price Target: $40.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +234.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,210,000.00
Net Margins: N/A
Pretax Margin: -10,514.71%
Return on Equity: -747.85%
Return on Assets: -115.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.56
Quick Ratio: 3.56

Sales & Book Value

Annual Sales: $11.07 million
Price / Sales: 25.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.51) per share
Price / Book: -6.93

Miscellaneous

Outstanding Shares: 26,720,000
Free Float: 23,592,000
Market Cap: $279.49 million
Optionable: Not Optionable
Beta: N/A

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Thomas Zindrick J.D. (Age 64)
Chairman, CEO & President
Comp: $500k
Mr. Sean Ryder J.D. (Age 54)
General Counsel & Corporate Secretary
Comp: $380k
Ms. Lourie S. Zak (Age 60)
CFO & Principal Accounting Officer
Dr. Joseph Cappello Ph.D. (Age 66)
Chief Technical Officer
Comp: $213.08k
Dr. Yong Yu Ph.D. (Age 52)
Senior Vice President of Clinical Development
Comp: $242.62k
Prof. Paul Scigalla M.D. (Age 77)
Ph.D., Chief Medical Officer
Mr. Ralph Smalling B.Sc. (Age 67)
Head of Regulatory Affairs
Ms. Caroline Jewett (Age 59)
Head of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genelux stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings or view top-rated stocks.
What is Genelux's stock price target for 2024?: 4 Wall Street research analysts have issued twelve-month price targets for Genelux's stock. Their GNLX share price targets range from $30.00 to $40.00. On average, they expect the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 234.6% from the stock's current price.
View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts.
How have GNLX shares performed in 2023?: Genelux's stock was trading at $6.01 at the beginning of 2023. Since then, GNLX stock has increased by 74.0% and is now trading at $10.46.
View the best growth stocks for 2023 here.
Are investors shorting Genelux?: Genelux saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 789,200 shares, a decrease of 8.8% from the October 31st total of 865,800 shares. Based on an average daily volume of 228,700 shares, the days-to-cover ratio is presently 3.5 days. Currently, 4.1% of the company's shares are short sold.
View Genelux's Short Interest.

When is Genelux's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our GNLX earnings forecast.
When did Genelux IPO?: (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.
Who are Genelux's major shareholders?: Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Provident Wealth Management LLC (1.36%), AE Wealth Management LLC (0.79%), Northern Trust Corp (0.61%), Charles Schwab Investment Management Inc. (0.56%), Bank of New York Mellon Corp (0.22%) and AMG National Trust Bank (0.19%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu.
View institutional ownership trends.
How do I buy shares of Genelux?: Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNLX) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genelux Stock Price, News & Analysis (NASDAQ:GNLX)

Genelux MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Genelux Stock (NASDAQ:GNLX)

GNLX Stock Price History

GNLX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GNLX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™